Given that cohesin directly regulates the DNA damage checkpoint activation and repair pathways and that tumors deficient in DNA damage response achieve durable benefit from ICB [117], STAG2-mutated AML might represent a promising subset for immunotherapy with ICB. Here, STAG2 is linked to acute myeloid leukemia.